Abstract:Background Proton pump inhibitors (PPIs) are usually prescribed to patients undergoing dual antiplatelet therapy to decrease the risk of gastrointestinal bleeding. However, the proportion of patients increased incidence of major adverse cardiovascular event because of interaction of PPIs and clopidogrel. The aim of the study was to assess the effect of omeprazole and pantoprazole on platelet reactivity in acute coronary syndrome patients receiving clopidogrel. Method From October 2012 to September 2013, a total of 620 consecutive acute coronary syndrome patients from Shenyang General Hospital were enrolled. All patients received clopidogrel loading dose 300 mg and aspirin 300 mg. Patients were randomised to two groups by the ratio of 1:1 and received routine dual anti-platelet treatment. The omeprazole group (aspirin 300 mg/d and clopidogrel 75 mg/d and omeprazole 20 mg/d, n = 310). The pantoprazole group (aspirin 300 mg/d and clopidogrel 75 mg/d and pantoprazole 20 mg/d, n = 310). The reversion rate of ADP which was defined as 20 μmol/L adenosine diphosphate induced platelet aggregation (by LTA) (on admission, three days and 30 days after dual antiplatelet therapy) and clinical events (stent thrombosis, MACEs, which included cardiac death, myocardial infarction or ischaemic symptoms driven target vessel revascularisation, all-cause death, TIMI) were observed. Result All groups were generally well balanced with regard to baseline demographic, clinical, and proced-ural characteristics. There were no different on platelet response to clopidogrel at three days (52.8% ± 19.3% vs 50.2% ± 19.3%, respectively, p = 0.384) and 30 days (49.9% ± 14.9% vs 49.1% ± 14.7%, respectively, p = 0.559) between omeprazole group and pantoprazole group. 1 stent thrombosis in the omeprazole group and 0 stent thrombosis in pantoprazole group (p = 0.219). 2 patients in omeprazole group were suffered from MACE (0.6%), and 3 patients in pantoprazole group (0.97%, p = 0.359). In addition, there were no major or minor bleeding in the two groups, the minimal bleeding in omeprazole and pantoprazole groups were no significantly difference (2.1% vs 2.8%, respectively, p = 0.235). There was no significantly association between the two groups for all-cause death (p = 0.687), and 1 patient died due to the traumatic brain injury in the omeprazole group. Conclusion These results suggest that the drug interaction between PPIs (omeprazole and pantoprazole)and clopidogrel does not result in ADP induced platelet aggregation. There was no apparent clinical events interaction between clopidogrel and omeprazole and pantoprazole in patients who received dual antiplatelet therapy. The clinic impact of this strategy needs to be proved by long term follow-up outcome studies.

Safety of Rebeprazole in Acute Coronary Syndrome Patients with Dual Anti-platelet Therapy after Percutaneous Coronary Intervention

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

Influence Of Ranitidine On Gastrointestinal Haemorrhage And Thrombosis Induced By Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials

ASSA14-03-35 Effects of Omeprazole and Pantoprazole on Platelet Function in Acute Coronary Syndrome Patients Receiving Clopidogrel: A Single-centre Prospective Randomised Controlled Clinical Trials

Efficacy and Safety of Ticagrelor Monotherapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Retrospective Study

The Safety of Long-term Combined Application of Rabeprazole and Clopidogrel in the Elderly

Use of Ticagrelor As Antiplatelet Therapy in Patients with Unstable Angina Pectoris after Undergoing Percutaneous Coronary Interventions:A Clinical Observation

Clinical Efficacy and Safety of Reduced-Dose Prasugrel After Percutaneous Coronary Intervention for Taiwanese Patients with Acute Coronary Syndromes

Clinical efficacy and safety of ticagrelor in acute coronary syndrome patients receiving percutaneous coronary intervention

Effects of Intensive Antiplatelet Therapy for Patients with High On-Treatment Platelet Reactivity after Coronary Stent Implantation

A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity

Impact of pantoprazole on clopidogrel's anti-platelet effect in patients with acute coronary syndrome

Effect of ticagrelor on acute coronary syndrome

Rabeprazole for preventing aspirin-related peptic ulcer in patients with cardiovascular diseases

The Efficacy and Safety of the Short‐term Combination Therapy with Ticagrelor and PPIs or H2RA in Patients with Acute STEMI Who Underwent Emergency PCI

Meta Analysis of Efficacy and Safety on Clopidogrel Combining Proton Pump Inhihibitor for Treating the Patients After Percutaneous Coronary Intervention

Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy

Abstract 15223: Comparison of Net Clinical Benefit Between Clopidogrel-based and Ticagrelor-based Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention in China

Efficacy and Safety of Different Antiplatelet Strategies in Survivors of Myocardial Infarction with Acute Coronary Syndrome

Effects of Rabeprazole on Pharmacokinetics of Clopidogrel in Rats